Immune thrombocytopenic purpura
ICD-10 D69.3 · ICD-11 3B64.10

Treatment of ITP in Adults When First-Line Corticosteroid Therapy Has Not Worked

Clinical Scenario

This protocol applies to adults (age ≥18 years) with immune thrombocytopenia (ITP) who have completed first-line corticosteroid therapy but have not achieved an adequate response.

Previous Treatment & Failure Condition

First-line therapy was a short course (≤6 weeks) of corticosteroids — either prednisone or dexamethasone. Escalation to this second-line protocol is triggered by failure to achieve a platelet count response at 7 days.

Second-Line Approach Partial Preview

For adults with ITP who are corticosteroid-dependent or have not responded to corticosteroids, individualized second-line therapy is recommended — one class of option involves a thrombopoietin receptor agonist. The complete selection algorithm, individualization criteria, and full regimen details are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

  1. In adults with newly diagnosed ITP, the ASH guideline panel recommends against a prolonged course (>6 weeks) of prednisone in favor of a short course (≤6 weeks) and suggests either prednisone (0.5–2.0 mg/kg/day) or dexamethasone (40 mg/day for 4 days) as the type of corticosteroid for initial therapy.
  2. In adults with ITP lasting ≥3 months who are corticosteroid-dependent or have no response to corticosteroids, the ASH guideline panel suggests the following as potential second-line therapies (see Figure 1): thrombopoietin receptor agonist (eltrombopag or romiplostim); rituximab; splenectomy. If possible, splenectomy should be delayed for at least one year after diagnosis because of the potential for spontaneous remission in the first year.
View source ↗